Table 1.
Main characteristics of the retained studies
| Characteristics of study | Studies with LTE prevalence (n = 37, %) | Studies with 1–year AE prevalence (n = 16, %) | Studies with 2–year AE prevalence (n = 12, %) | Studies with 5–year AE prevalence (n = 12, %) |
|---|---|---|---|---|
|
Year published: | ||||
| 1990–1999 |
12 (32.4) |
0 (0.0) |
0 (0.0) |
0 (0.0) |
| 2000–2009 |
16 (43.2) |
11 (68.8) |
8 (66.7) |
7 (58.3) |
| 2010–2016 |
9 (24.3) |
5 (31.3) |
4 (33.3) |
5 (41.7) |
|
Setting: | ||||
| Urban |
4 (10.8) |
1 (6.3) |
1 (8.3) |
1 (8.3) |
| Rural |
21 (56.8) |
14 (87.5) |
10 (83.3) |
10 (83.3) |
| Mixed |
9 (24.3) |
1 (6.3) |
1 (8.3) |
1 (8.3) |
| Both |
3 (8.1) |
0 (0.0) |
0 (0.0) |
0 (0.0) |
|
Sample size: | ||||
| 4000–10 000 |
9 (24.3) |
2 (12.5) |
1 (8.3) |
1 (8.3) |
| 10 001–50 000 |
17 (45.9) |
11 (68.8) |
9 (75.0) |
10 (83.3) |
| 50 001–200 000 |
8 (21.6) |
2 (12.5) |
2 (16.7) |
1 (8.3) |
| 200 001–900 000 |
3 (8.1) |
1 (6.3) |
0 (0.0) |
0 (0.0) |
|
Screening tool: |
||||
| WHO questionnaire |
14 (37.8) |
9 (56.3) |
7 (58.3) |
7 (58.3) |
| ICBERG questionnaire |
5 (13.5) |
4 (25.0) |
4 (33.3) |
4 (33.3) |
| Self–designed questionnaire |
10 (27) |
1 (6.3) |
0 (0.0) |
0 (0.0) |
| Questionnaire based on ILAE/CMA/ BNI diagnosis |
7 (18.9) |
2 (12.5) |
1 (8.3) |
1 (8.3) |
| Not specified |
1 (2.7) |
0 (0.0) |
0 (0.0) |
0 (0.0) |
|
Diagnosis of epilepsy: |
||||
| By neurologists |
27 (73.0) |
12 (75.0) |
9 (75.0) |
10 (83.3) |
| By trained physicians |
6 (16.2) |
3 (18.8) |
2 (16.7) |
2 (16.7) |
| By trained investigators |
2 (5.4) |
0 (0.0) |
0 (0.0) |
0 (0.0) |
| Not specified | 2 (5.4) | 1 (6.3) | 1 (8.3) | 0 (0.0) |
LTE – lifetime epilepsy, AE – active epilepsy, WHO – World Health Organization, ICBERG – International Community–based Epilepsy Research Group, ILAE – International League Against Epilepsy, CMA – Chinese Medical Association, BNI – Beijing Neurosurgical Institute